Cas no 147849-82-9 (6-tert-butyl-2,3-dihydropyridazin-3-one)
6-tert-butyl-2,3-dihydropyridazin-3-one Chemical and Physical Properties
Names and Identifiers
-
- 3-tert-butyl-1h-pyridazin-6-one
- 6-tert-butyl-2,3-dihydropyridazin-3-one
- 3(2H)-Pyridazinone, 6-(1,1-dimethylethyl)-
- AC1MCWXH
- AC1Q1MEF
- Maybridge4_000681
- SureCN2627805
- SureCN3176447
- ACMC-1C682
- 6-(TERT-BUTYL)PYRIDAZIN-3(2H)-ONE
- HMS1522O21
- DB-369391
- TUDXTYPISQDTPK-UHFFFAOYSA-N
- 147849-82-9
- EN300-66802
- SR-01000634225-1
- IDI1_031263
- CCG-44386
- DTXSID50384342
- F8889-3587
- AKOS008135766
- 6-TERT-BUTYL-2H-PYRIDAZIN-3-ONE
- 6-tert-butylpyridazin-3(2H)-one
- SCHEMBL2627805
- BRD-K68940208-001-01-9
- Z432063054
- F51252
-
- MDL： MFCD01312126
- Inchi： 1S/C8H12N2O/c1-8(2,3)6-4-5-7(11)10-9-6/h4-5H,1-3H3,(H,10,11)
- InChI Key： TUDXTYPISQDTPK-UHFFFAOYSA-N
- SMILES： O=C1C=CC(C(C)(C)C)=NN1
Computed Properties
- Exact Mass: 152.09506
- Monoisotopic Mass: 152.094963011g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 11
- Rotatable Bond Count: 1
- Complexity: 233
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 1
- Topological Polar Surface Area: 41.5?2
Experimental Properties
- PSA: 41.46
6-tert-butyl-2,3-dihydropyridazin-3-one Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Alichem | A029184518-5g |
6-(tert-Butyl)pyridazin-3(2H)-one |
147849-82-9 | 97% | 5g |
1,460.60 USD | 2021-06-01 | |
| Alichem | A029184518-10g |
6-(tert-Butyl)pyridazin-3(2H)-one |
147849-82-9 | 97% | 10g |
2,090.40 USD | 2021-06-01 | |
| Alichem | A029184518-25g |
6-(tert-Butyl)pyridazin-3(2H)-one |
147849-82-9 | 97% | 25g |
3,383.50 USD | 2021-06-01 | |
| TRC | B789680-25mg |
6-tert-butyl-2,3-dihydropyridazin-3-one |
147849-82-9 | 25mg |
$ 50.00 | 2022-06-06 | ||
| TRC | B789680-50mg |
6-tert-butyl-2,3-dihydropyridazin-3-one |
147849-82-9 | 50mg |
$ 70.00 | 2022-06-06 | ||
| TRC | B789680-250mg |
6-tert-butyl-2,3-dihydropyridazin-3-one |
147849-82-9 | 250mg |
$ 295.00 | 2022-06-06 | ||
| CHENG DOU FEI BO YI YAO Technology Co., Ltd. | FC13716-10g |
6-(tert-butyl)pyridazin-3(2H)-one |
147849-82-9 | 95% | 10g |
$1500 | 2023-09-07 | |
| Chemenu | CM411843-1g |
6-(tert-butyl)pyridazin-3(2H)-one |
147849-82-9 | 95%+ | 1g |
$418 | 2023-03-07 | |
| Enamine | EN300-66802-0.05g |
6-tert-butyl-2,3-dihydropyridazin-3-one |
147849-82-9 | 95% | 0.05g |
$64.0 | 2023-05-03 | |
| Enamine | EN300-66802-0.1g |
6-tert-butyl-2,3-dihydropyridazin-3-one |
147849-82-9 | 95% | 0.1g |
$83.0 | 2023-05-03 |
6-tert-butyl-2,3-dihydropyridazin-3-one Suppliers
Audited Supplier
6-tert-butyl-2,3-dihydropyridazin-3-one Related Literature
-
M. Sheykhan,S. Khani,S. Shaabanzadeh,M. Joafshan Green Chem., 2017,19, 5940-5948
-
Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
-
3. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
-
Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
-
5. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
Additional information on 6-tert-butyl-2,3-dihydropyridazin-3-one
Introduction to 6-tert-butyl-2,3-dihydropyridazin-3-one (CAS No. 147849-82-9)
6-tert-butyl-2,3-dihydropyridazin-3-one, with the Chemical Abstracts Service (CAS) number 147849-82-9, is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyridazines, which are six-membered heterocyclic compounds containing two nitrogen atoms. The presence of the tert-butyl group and the dihydropyridazine structure imparts unique chemical and biological properties to this molecule, making it a valuable candidate for various applications.
The chemical structure of 6-tert-butyl-2,3-dihydropyridazin-3-one is characterized by a six-membered ring with two nitrogen atoms at positions 1 and 4, and a tert-butyl group attached to the carbon at position 6. The dihydropyridazine structure indicates that the ring is partially saturated, with a double bond between the nitrogen atoms. This structural configuration contributes to its stability and reactivity, which are crucial factors in its potential pharmaceutical applications.
Recent studies have explored the biological activities of 6-tert-butyl-2,3-dihydropyridazin-3-one, revealing its potential as a therapeutic agent. One notable area of research is its anti-inflammatory properties. In vitro and in vivo studies have demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These findings suggest that 6-tert-butyl-2,3-dihydropyridazin-3-one could be a promising candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
In addition to its anti-inflammatory effects, 6-tert-butyl-2,3-dihydropyridazin-3-one has also shown potential as an antioxidant. Oxidative stress is a key factor in the development of various diseases, including neurodegenerative disorders and cardiovascular diseases. Research has indicated that this compound can scavenge free radicals and reduce oxidative damage, thereby protecting cells from oxidative stress-induced injury. This property makes it a potential therapeutic agent for conditions where oxidative stress plays a significant role.
The pharmacokinetic properties of 6-tert-butyl-2,3-dihydropyridazin-3-one have also been investigated. Studies have shown that it has good oral bioavailability and favorable pharmacokinetic profiles, which are essential for its development as an oral medication. The compound's ability to cross the blood-brain barrier has also been evaluated, indicating its potential for treating central nervous system (CNS) disorders.
Clinical trials are currently underway to further evaluate the safety and efficacy of 6-tert-butyl-2,3-dihydropyridazin-3-one. Preliminary results from phase I trials have demonstrated that it is well-tolerated by patients with minimal side effects. These findings are encouraging and support the continued development of this compound as a potential therapeutic agent.
In conclusion, 6-tert-butyl-2,3-dihydropyridazin-3-one (CAS No. 147849-82-9) is a promising compound with diverse biological activities. Its anti-inflammatory and antioxidant properties make it a valuable candidate for the treatment of various diseases. Ongoing research and clinical trials will provide further insights into its therapeutic potential and pave the way for its use in clinical practice.
147849-82-9 (6-tert-butyl-2,3-dihydropyridazin-3-one) Related Products
- 13327-27-0(3-methyl-1H-pyridazin-6-one)
- 88372-17-2(3(2H)-Pyridazinone, 6-(1-ethylcyclohexyl)-)
- 679405-98-2(3(2H)-Pyridazinone, 6-methyl-5-propyl- (9CI))
- 88372-16-1(3(2H)-Pyridazinone, 6-(1,1-dimethylethyl)-, hydrochloride (1:1))
- 87539-11-5(3(2H)-Pyridazinone, 6-(1-ethyl-1-methylpropyl)-)
- 73619-57-5(6-Methylpyridazin-3-one)
- 570416-36-3(6-Isopropyl-3-pyridazinone)
- 7143-82-0(3-methyl-1H-pyridazin-6-one;hydrate)
- 39716-45-5(2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-3-one)
- 94248-99-4(3-methyl-1H-pyridazin-6-one;hydrobromide)
